Description
A sphingolipid; inhibits PMA-induced aggregation of human neutrophils (1 μM); acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes; accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease; accumulates in various cells in patients with Fabry disease
Formal name: N-[(1S,2R,3E)-1-[[(O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl)oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]-octadecanamide
Synonyms: C18 Ceramide Trihexoside (d18:1/18:0)|Gb3(d18:1/18:0)
Molecular weight: 1,052.40
CAS: 69283-33-6
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Endocrinology & Metabolism|Inborn Errors of Metabolism||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Infectious Disease|Bacterial Diseases|Shigellosis||Research Area|Lipid Biochemistry|Sphingolipids||Research Area|Neuroscience